• About us
• Contact

Advertisement

Person › Details

Mondher Majhoubi (Innate Pharma S.A. (Euronext Paris: IPH, Nasdaq: IPHA))

Mahjoubi, Mondher (Innate Pharma 201612– CEO before AstraZeneca + Genentech + Aventis + Sanofi)

 

	Organisation	Innate Pharma S.A. (Euronext Paris: IPH, Nasdaq: IPHA)
	Product	therapeutic antibody
	Product 2	cancer immunotherapy (immuno-oncology, I-O)

Record changed: 2020-06-26

Advertisement

More documents for Mondher Majhoubi

• [1] PDC*line Pharma S.A.. (6/25/20). "Press Release: PDC*line Pharma Welcomes Dr. Mondher Mahjoubi as Chairman of Its Board of Directors". Liège & Grenoble....
• [2] Innate Pharma S.A.. (11/13/19). "Press Release: Innate Pharma Third Quarter 2019 Report"....
• [3] Innate Pharma S.A.. (10/23/18). "Press Release: Innate Pharma Strengthens and Expands Its Oncology Development Collaboration with AstraZeneca". Marseille....
• [4] Innate Pharma S.A.. (5/16/18). "Press Release: First Quarter 2018 Report". Marseille....
• [5] Innate Pharma S.A.. (1/30/18). "Press Release: Innate Pharma and MedImmune Enter Clinical Trial Collaboration". Marseille....
• [6] Innate Pharma S.A.. (6/2/17). "Press Release: Innate Pharma Strenghtens Its Proprietary Pipeline with the Acquisition of anti-C5aR, a First-in-class Clinical-stage Antibody from Novo Nordisk A/S". Marseille....
• [7] Innate Pharma S.A.. (1/4/17). "Press Release: Upcoming Investor Conferences". Marseille....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.